OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest...
MarketBeat·3d ago
More News
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short...
MarketBeat·14d ago
OKYO Pharma (NASDAQ:OKYO) Trading Down 15.5% - What's Next?
OKYO Pharma (NASDAQ:OKYO) Shares Down 15.5% - Should You Sell...
MarketBeat·15d ago
OKYO Pharma CEO Gary Jacob Transitions To CDO; Appoints Robert Dempsey As CEO
(RTTNews) - OKYO Pharma Ltd. (OKYO), on Monday, said it has appointed Robert Dempsey as Chief Executive Officer, effective immediately...
Nasdaq News: Markets·26d ago
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totaling...
MarketBeat·1mo ago
OKYO Pharma (NASDAQ:OKYO) Stock Rating Upgraded by B. Riley
B. Riley raised OKYO Pharma to a "strong-buy" rating and set a $5.00 target price for the company in a research report on Monday...
MarketBeat·2mo ago
OKYO Pharma (NASDAQ:OKYO) Shares Down 4.5% - Time to Sell?
OKYO Pharma (NASDAQ:OKYO) Shares Down 4.5% - Here's Why...
MarketBeat·2mo ago
OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug
Okyo announced on Monday that it is now focused on advancing to a multiple-ascending-dose clinical trial, designed to enroll approximately 100 patients with neuropathic corneal pain across several U.S. clinical sites.